Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world

PLoS ONE

Volumn 14, Issue 1, 2019, Pages

  Zarranz Ventura, Javier ^a   Sala Puigdollers, Anna ^a   Velazquez Villoria, Daniel ^b   Figueras Roca, Marc ^a   Copete, Sergio ^b   Distefano, Laura ^b   Boixadera, Anna ^b   García Arumi, Jose ^b   Adan, Alfredo ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

AGED; ARTICLE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLAUCOMA; GLAUCOMA SURGERY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; PATIENT RISK; TREATMENT OUTCOME; KAPLAN MEIER METHOD; MACULAR EDEMA; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA VEIN OCCLUSION; UVEITIS;

AGED; DEXAMETHASONE; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; KAPLAN-MEIER ESTIMATE; MACULAR EDEMA; MALE; OCULAR HYPERTENSION; RETINAL VEIN OCCLUSION; UVEITIS;

EID: 85059444613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0209997     Document Type: Article

References (21)

1. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 2014; 121:1904–1914. https://doi.org/10.1016/j.ophtha.2014.04.024 PMID: 24907062
2. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD et al. Pharma-cokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011; 52:80–86. https://doi.org/10.1167/iovs.10-5285 PMID: 20702826
3. Whitcup SM and Robinson MR. Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis. Ann N Y Acad Sci 2015; 1358:1–12. https://doi.org/10.1111/nyas.12824 PMID: 26200808
4. Robinson MR and Whitcup SM. Pharmacologic and clinical profile of dexamethasone intravitreal implant. Expert Rev Clin Pharmacol 2012; 5:629–647. https://doi.org/10.1586/ecp.12.55 PMID: 23234323
5. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117:1134–1146 e1133. https://doi.org/10.1016/j.ophtha.2010.03.032PMID: 20417567
6. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelvemonth study results. Ophthalmology 2011; 118:2453–2460. https://doi.org/10.1016/j.ophtha.2011.05. 014 PMID: 21764136
7. Boyer DS, Faber D, Gupta S, Patel SS, Tabandeh H, Li XY et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 2011; 31:915–923. https://doi.org/10.1097/IAE.0b013e318206d18c PMID: 21487341
8. Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129:545–553. https://doi.org/10.1001/archophthalmol.2010.339 PMID: 21220619
9. Zarranz-Ventura J, Carreño E, Johnston RL, Mohammed Q, Ross AH, Barker C et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol 2014; 158:1136–1145 e1135. https://doi.org/10.1016/j.ajo.2014.09.003PMID: 25217856
10. Chhablani J, Bansal P, Veritti D, Sambhana S, Sarao V, Pichi F et al. Dexamethasone implant in diabetic macular edema in real-life situations. Eye (Lond) 2016; 30:426–430.
11. Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 2015; 9:1255–1268. https://doi.org/10.2147/OPTH.S80500 PMID: 26203215
12. Adan A, Pelegrin L, Rey A, Llorenç V, Mesquida M, Molins B et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 2013; 33:1435–1440. https://doi.org/10.1097/IAE.0b013e31827e247b PMID: 23514796
13. Arcinue CA, Ceron OM and Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. Journal of ocular pharmacology and therapeutics: the official journal of the Association for Ocular Pharmacology and Therapeutics 2013; 29:501–507.
14. Tomkins-Netzer O, Taylor SR, Bar A, Lula A, Yaganti S, Talat L et al. Treatment with Repeat Dexamethasone Implants Results in Long-Term Disease Control in Eyes with Noninfectious Uveitis. Ophthalmology 2014; 121(8):1649–54. https://doi.org/10.1016/j.ophtha.2014.02.003 PMID: 24650556
15. Capone A Jr., Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 2014; 34:342–351. https://doi.org/10.1097/IAE. 0b013e318297f842 PMID: 23846381
16. Maturi RK, Pollack A, Uy HS, Varano M, Gomes AM, Li XY et al. Intraocular Pressure in Patients with Diabetic Macular Edema Treated with Dexamethasone Intravitreal Implant in the 3-Year Mead Study. Retina 2016; 36:1143–1152. https://doi.org/10.1097/IAE.0000000000001004 PMID: 26871523
17. Lange C, Feltgen N, Junker B, Schulze-Bonsel K, Bach M. Resolving the clinical acuity categories "hand motion" and "counting fingers" using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol 2009; 247:137–142. https://doi.org/10.1007/s00417-008-0926-0 PMID: 18766368
18. Kaplan E and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457–481.
19. Malcles A, Dot C, Voirin N, Vié AL, Agard É, Bellocq D et al. SAFETY OF INTRAVITREAL DEXAMETH-ASONE IMPLANT (OZURDEX): The SAFODEX study. Incidence and Risk Factors of Ocular Hypertension. Retina 2017; 37(7):1352–1359. https://doi.org/10.1097/IAE.0000000000001369 PMID: 27768641
20. Mazzarella S, Mateo C, Freixes S, Burés-Jelstrup A, Rios J, Navarro R et al. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex(R)) on intraocular pressure in patients with macular edema. Ophthalmic Res 2015; 54:143–149. https://doi.org/10.1159/000438759 PMID: 26394206
21. Jimenez-Gomez B, Gonzalez-Montpetit M, Fonollosa Calduch A, Orive Bañuelos A, Valsero Franco S. [Effects of ozurdex on intraocular pressure. A real life clinical practice study]. Arch Soc Esp Oftalmol 2015; 90:421–425. https://doi.org/10.1016/j.oftal.2015.01.006 PMID: 25817950